ESMO HIGHLIGHTS

June 9, 2021

Esmo Breast Cancer 2021: analysis of two important studies presented during the congress

Clinical Oncologist at Grupo Oncoclínicas discusses phase II DESTINY-Breast01 study and meta-analysis that included four randomized clinical trials involving patients with triple-negative breast cancer    The ESMO Breast Cancer 2021 event, held […]
October 22, 2020

CodeBreak 100: results show durability of clinical benefit with sotorasib in patients with non-small cell lung cancer

Durability of clinical benefit and biomarkers in patients with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). CodeBreaK 100 is an important, multicenter, […]
October 22, 2020

SPARTAN: quality of life related to the use of apalutamide in patients with castration-resistant non-metastatic prostate cancer

There were no therapeutic options specifically approved for the population of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), but the evolution of therapeutic options has been […]
October 21, 2020

Study assesses benefit of erdafitinib in patients with advanced urothelial carcinoma and FGFR mutation

Study results BLC2001 (757P – An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death- (Ligand) 1 (PD- [L] 1) […]
October 21, 2020

Olaparib stands out as a treatment option in patients with castration-resistant metastatic prostate cancer

See the results of the PROfound trial presented at ESMO Virtual Congress 2020, whose updates of global survival data were published in the New England Journal […]
October 20, 2020

ESMO 2020: Impact of new studies in the treatment of lung cancer

Three main clinical trials for EGFR mutation non-small cell lung carcinoma presented at ESMO Virtual Congress 2020. FLAURA 2 The partial results of this trial that […]